Literature DB >> 30465092

Quantitation and distribution of metallic elements in sequestra of medication-related osteonecrosis of jaw (MRONJ) using inductively coupled plasma atomic emission spectroscopy and synchrotron radiation X-ray fluorescence analysis.

Ruri Komiya1, Takahiro Wada2, Fumihiko Tsushima1, Kei Sakamoto3, Tohru Ikeda3, Akira Yamaguchi3,4, Hiroyuki Harada1, Motohiro Uo5,6.   

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse effect of antiresorptive agents like bisphosphonates. Abnormal concentrations of various trace metallic elements contained in bone minerals have been associated with MRONJ. In this study, we focused on trace metallic elements contained in the MRONJ sequestrum; their content and distribution were compared to those in osteomyelitis and non-inflammatory bones using inductively coupled plasma atomic emission spectroscopy (ICP-AES) and synchrotron radiation X-ray fluorescence analysis (SR-XRF). On ICP-AES analyses, various trace elements (Co, Cr, Cu, Fe, K, Mg, Ni, Sb, Ti, V, Pb) were significantly more in MRONJ sequestra than non-inflammatory bones. The Cu content was significantly higher in MRONJ sequestra than osteomyelitis and non-inflammatory bones. The Cu content in MRONJ sequestra was high even after decalcification. Additionally, Cu was distributed along the trabecular structures in decalcified MRONJ specimens, as observed using SR-XRF analysis. Therefore, this study was indicative of the characteristic behavior of Cu in MRONJ.

Entities:  

Keywords:  Inductively coupled plasma atomic emission spectroscopy (ICP-AES); Medication-related osteonecrosis of the jaw (MRONJ); Synchrotron radiation X-ray fluorescence analysis (SR-XRF); Trace metallic element

Mesh:

Substances:

Year:  2018        PMID: 30465092     DOI: 10.1007/s00774-018-0975-3

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  21 in total

1.  Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates.

Authors:  Jin-Woo Kim; Kyoung-Ae Kong; Sun-Jong Kim; Sung-Keun Choi; In-Ho Cha; Myung-Rae Kim
Journal:  Bone       Date:  2013-08-14       Impact factor: 4.398

2.  Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.

Authors:  Joan C Lo; Felice S O'Ryan; Nancy P Gordon; Jingrong Yang; Rita L Hui; Daniel Martin; Matthew Hutchinson; Phenius V Lathon; Gabriela Sanchez; Paula Silver; Malini Chandra; Carolyn A McCloskey; Judy A Staffa; Mary Willy; Joe V Selby; Alan S Go
Journal:  J Oral Maxillofac Surg       Date:  2009-09-24       Impact factor: 1.895

Review 3.  Is there a potential therapeutic value of copper and zinc for osteoporosis?

Authors:  Nicola M Lowe; Nicola M Lowe; William D Fraser; Malcolm J Jackson
Journal:  Proc Nutr Soc       Date:  2002-05       Impact factor: 6.297

4.  Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.

Authors:  Robert E Marx; Joseph E Cillo; Juan J Ulloa
Journal:  J Oral Maxillofac Surg       Date:  2007-12       Impact factor: 1.895

5.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

Review 6.  Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis.

Authors:  Elise Gaudin; Laurence Seidel; Miljana Bacevic; Eric Rompen; France Lambert
Journal:  J Clin Periodontol       Date:  2015-11-03       Impact factor: 8.728

7.  Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Konstantinos Vahtsevanos; Athanassios Kyrgidis; Evgenia Verrou; Eirini Katodritou; Stefanos Triaridis; Charalampos G Andreadis; Ioannis Boukovinas; Georgios E Koloutsos; Zisis Teleioudis; Kyriaki Kitikidou; Panagiotis Paraskevopoulos; Konstantinos Zervas; Konstantinos Antoniades
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

8.  Basic fibroblast growth factor attenuates bisphosphonate-induced oxidative injury but decreases zinc and copper levels in oral epithelium of rat.

Authors:  Gülperi Koçer; Mustafa Nazıroğlu; Ömer Çelik; Levent Önal; Derviş Özçelik; Murat Koçer; Tolga Taha Sönmez
Journal:  Biol Trace Elem Res       Date:  2013-04-10       Impact factor: 3.738

9.  Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

Authors:  R Coleman; E Woodward; J Brown; D Cameron; R Bell; D Dodwell; M Keane; M Gil; C Davies; R Burkinshaw; S J Houston; R J Grieve; P J Barrett-Lee; H Thorpe
Journal:  Breast Cancer Res Treat       Date:  2011-03-11       Impact factor: 4.872

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

View more
  2 in total

Review 1.  Pathophysiology of Demineralization, Part I: Attrition, Erosion, Abfraction, and Noncarious Cervical Lesions.

Authors:  W Eugene Roberts; Jonathan E Mangum; Paul M Schneider
Journal:  Curr Osteoporos Rep       Date:  2022-02-07       Impact factor: 5.096

Review 2.  Pathophysiology of Demineralization, Part II: Enamel White Spots, Cavitated Caries, and Bone Infection.

Authors:  W Eugene Roberts; Jonathan E Mangum; Paul M Schneider
Journal:  Curr Osteoporos Rep       Date:  2022-02-14       Impact factor: 5.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.